Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,850 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Recruiting No phase listed Observational

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 16 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 27, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

NCT04718870
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 27, 2026, 2:27 AM EDT
Completed No phase listed Observational

Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))

NCT01880983
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP)
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
7 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 27, 2026, 2:27 AM EDT
Available No phase listed Expanded access

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

NCT05795361
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT
Drug
Lead sponsor
Takeda
Industry
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Phoenix, Arizona • Oakland, California • Wilmington, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 27, 2026, 2:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OTIS Humira Pregnancy Registry

NCT01086059
View directory record Official record
Conditions
Crohn's Disease, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 27, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

A Study of RG-012 in Subjects With Alport Syndrome

NCT03373786
View directory record Official record
Conditions
Alport Syndrome
Interventions
RG012
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
La Mesa, California • Los Angeles, California • Riverside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 27, 2026, 2:27 AM EDT
Recruiting No phase listed Observational

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

NCT06988605
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 27, 2026, 2:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Gentamicin for Junctional Epidermolysis Bullosa

NCT03526159
View directory record Official record
Conditions
Junctional Epidermolysis Bullosa
Interventions
Gentamicin Sulfate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 27, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

NCT00002673
View directory record Official record
Conditions
Cancer
Interventions
infection prophylaxis and management
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 27, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 27, 2026, 2:27 AM EDT
Withdrawn No phase listed Observational

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

NCT04214002
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 27, 2026, 2:27 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Pirfenidone Treatment in HPS-ILD

NCT04193592
View directory record Official record
Conditions
Hermansky Pudlak Syndrome, Interstitial Lung Disease
Interventions
Pirfenidone
Drug
Lead sponsor
Jesse Roman
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 27, 2026, 2:27 AM EDT
Terminated No phase listed Observational

Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

NCT06411132
View directory record Official record
Conditions
Sjögren Syndrome, Dry Eye
Interventions
observational study
Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 27, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Eucrisa for Atopic Dermatitis

NCT03250663
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
Online Treatment response, EUCRISA
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 27, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

NCT06005792
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
XmAb27564, Placebo
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Sherman Oaks, California • Thousand Oaks, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 27, 2026, 2:27 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease

NCT00515398
View directory record Official record
Conditions
Pompe Disease, Glycogen Storage Disease Type II
Interventions
Observation
Other
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Gainesville, Florida • St Louis, Missouri • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Oct 27, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03575871
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 27, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, AIN 457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 27, 2026, 2:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

NCT03406611
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase, Placebo
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 27, 2026, 2:27 AM EDT
Withdrawn Not applicable Interventional

Treatment of Benign Breast Deformities and Post-Segmental Mastectomy Breast Deformities With Autologous Fat Grafting (AFT)

NCT01756092
View directory record Official record
Conditions
Breast Cancer, Lumpectomy, Mastectomy, Segmental
Interventions
Autologous Fat Graft
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 27, 2026, 2:27 AM EDT
Completed No phase listed Observational

Impact of Vasculitis on Employment and Income

NCT02476292
View directory record Official record
Conditions
Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis, Temporal Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa (PAN), Takayasu's Arteritis, Urticarial Vasculitis
Interventions
online questionnaire
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 27, 2026, 2:27 AM EDT
Completed Phase 3 Interventional

Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

NCT00232011
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream 1%
Drug
Lead sponsor
Novartis
Industry
Eligibility
16 Years to 65 Years
Enrollment
160 participants
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Oct 27, 2026, 2:27 AM EDT
Active, not recruiting Phase 1 Interventional

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

NCT06928246
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2
Drug
Lead sponsor
Daniel Kaplan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 2:27 AM EDT
Not listed Phase 1Phase 2 Interventional

Optimizing IV Gentamicin in JEB

NCT04140786
View directory record Official record
Conditions
Junctional Epidermolysis Bullosa
Interventions
Gentamicin Sulfate, Injectable
Drug
Lead sponsor
University of Southern California
Other
Eligibility
30 Days and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 27, 2026, 2:27 AM EDT